×
As ‘Scream 7’ Arrives, Its Studios Fight to Own Ghostface’s… Uh, Face

As ‘Scream 7’ Arrives, Its Studios Fight to Own Ghostface’s… Uh, Face

Scream 7 hits theaters at the end of this month, and the promo game is gradually building up. While Sidney Prescott fights another Ghostface or two, franchise owners Paramount and Spyglass are in a legal fight for the rights to the villain’s iconic mask.

Per the Hollywood Reporter, the two companies are taking SFX studio Alterian Ghost Factory to court before it can threaten copyright infringement. With this suit, Paramount and Spyglass hope to file a court order to prevent Alterian’s suit, claiming the company “intentionally slept on its purported rights in the iconic ‘Ghostface’ mask used throughout the Scream franchise for 30 years.”

The Ghostface mask was developed for Halloween in the early ’90s by Fun World and later discovered by Scream producer Marianne Maddalena. It was later licensed for the movie and featured throughout the franchise and its different sequels, with the one exception being the MTV show. Alterian’s arguing that since it created the underlying design first, Fun World was in the legal wrong when it licensed out the final version to Paramount. Conversely, Paramount believes Fun World deserves Alterian’s ire and that Alterian lost any right to call ownership of Ghostface after spending decades without taking any legal action.

“[It] has never legally established that it owns the rights to the Ghostface mask, and it will not be able to prove it now in this litigation,” reads Paramount’s complaint. “And seeking to disrupt the release of a completed motion picture mere weeks before its release—the seventh installment of a franchise that Alterian watched grow in silence for three decades—is an outrageous attempt to shake down [Paramount and Spyglass].”

Scream 7 is in theaters on February 27, and the legal fight for Ghostface may continue beyond that date.

Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what’s next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.

Source link
#Scream #Arrives #Studios #Fight #Ghostfaces.. #Face

Samsung has unveiled a new flexible display technology for foldable phones that’s designed to be slimmer, more durable, and less prone to creasing. The Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.

As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.

A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.

“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”

Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.

#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech">Samsung’s new foldable display is harder to crease and damageSamsung has unveiled a new flexible display technology for foldable phones that’s designed to be slimmer, more durable, and less prone to creasing. The Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech

Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.

As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.

A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.

“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”

Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.

#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech">Samsung’s new foldable display is harder to crease and damage

Samsung has unveiled a new flexible display technology for foldable phones that’s designed to be slimmer, more durable, and less prone to creasing. The Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.

As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.

A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.

“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”

Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.

#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI">OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at B | TechCrunch
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about 0 million at a  billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.







Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised 0 million at a .8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a .1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI

Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI">OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B | TechCrunch

Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI

Post Comment